Skip to main content

Potential for methotrexate exposure through contamination during parenteral use as an immunosuppressant

Buy Article:

$51.00 plus tax (Refund Policy)


Background: To evaluate whether the risk of methotrexate (MTX) exposure through skin contamination using parenteral doses of 25 mg warrants special oncology handling precautions during administration.

Keywords: handling precautions; methotrexate; rheumatoid arthritis; skin contamination; toxicity

Document Type: Research Article


Publication date: 2009-06-01

  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more